LLY Jan 2025 840.000 call
- Yahoo Finance
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand. What does that mean for the marketplace?
- Yahoo Finance Video
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
Eli Lilly's (LLY) GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors, like Novo Nordisk (NVO). For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
- Zacks
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.
